Vifor Fresenius Medical Care Renal Pharma Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Vifor Fresenius Medical Care Renal Pharma Ltd.
Plus alliances involving Xyphos/Kelonia, Nippon Shinyaku/Vicor, Telix/QSAM, Nicox/Kowa, Kyowa Kirin/BridgeBio, as well as deals in brief.
The European Medicines Agency is due to decide whether to back pan-EU marketing authorization for 11 new products, including four orphan drugs.
CSL’s evolution from plasma fractioneer to biotech has reached the extent of an approved gene therapy just as gene therapy commercialization faces challenges. Meanwhile, in the post-pandemic inflationary environment, CSL’s margins in its biggest blood products division are impacted by increased donor fees and higher labor costs.
The latest data from a Phase I/II study shows that pegtibatinase can yield a rapid, sustained reduction in homocysteine, the protein behind the underlying cause of the rare disease.
- Specialty Pharmaceuticals
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.